1-1 of 1
Steffi Oeyen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost, Wim Demey, Lucien Hoekx, Dirk Schrijvers, Barbara Brouwers, Willem Lybaert, Els G. Everaert, Daan De Maeseneer, Michiel Strijbos, Alain Bols, Karen Fransis, Nick Beije, Inge E. de Kruijff, Valerie van Dam, Anja Brouwer, Dirk Goossens, Lien Heyrman, Gert G. Van den Eynden, Annemie Rutten, Jurgen Del Favero, Mattias Rantalainen, Prabhakar Rajan, Stefan Sleijfer, Anders Ullén, Jeffrey Yachnin, Henrik Grönberg, Steven J. Van Laere, Johan Lindberg, Luc Y. Dirix
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (6): 1766–1773.
https://doi.org/10.1158/1078-0432.CCR-18-1943
Published: 15 March 2019
View article titled, <em>TP53</em> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Open the PDF for <em>TP53</em> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data